1730 related articles for article (PubMed ID: 21444866)
1. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Ychou M; Boige V; Pignon JP; Conroy T; Bouché O; Lebreton G; Ducourtieux M; Bedenne L; Fabre JM; Saint-Aubert B; Genève J; Lasser P; Rougier P
J Clin Oncol; 2011 May; 29(13):1715-21. PubMed ID: 21444866
[TBL] [Abstract][Full Text] [Related]
2. The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice.
Chua YJ; Cunningham D
Ann Surg Oncol; 2007 Oct; 14(10):2687-90. PubMed ID: 17653804
[No Abstract] [Full Text] [Related]
3. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.
Bamias A; Hill ME; Cunningham D; Norman AR; Ahmed FY; Webb A; Watson M; Hill AS; Nicolson MC; O'Brien ME; Evans TC; Nicolson V
Cancer; 1996 May; 77(10):1978-85. PubMed ID: 8640659
[TBL] [Abstract][Full Text] [Related]
4. A nationwide retrospective study of perioperative chemotherapy for gastroesophageal adenocarcinoma: tolerability, outcome, and prognostic factors.
Larsen AC; Holländer C; Duval L; Schønnemann K; Achiam M; Pfeiffer P; Yilmaz MK; Thorlacius-Ussing O; Bæksgaard L; Ladekarl M
Ann Surg Oncol; 2015 May; 22(5):1540-7. PubMed ID: 25348777
[TBL] [Abstract][Full Text] [Related]
5. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Al-Batran SE; Hartmann JT; Probst S; Schmalenberg H; Hollerbach S; Hofheinz R; Rethwisch V; Seipelt G; Homann N; Wilhelm G; Schuch G; Stoehlmacher J; Derigs HG; Hegewisch-Becker S; Grossmann J; Pauligk C; Atmaca A; Bokemeyer C; Knuth A; Jäger E;
J Clin Oncol; 2008 Mar; 26(9):1435-42. PubMed ID: 18349393
[TBL] [Abstract][Full Text] [Related]
6. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
[TBL] [Abstract][Full Text] [Related]
7. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
Molina R; Lamarca A; Martínez-Amores B; Gutiérrez A; Blázquez A; López A; Granell J; Álvarez-Mon M
Eur J Surg Oncol; 2013 Aug; 39(8):814-22. PubMed ID: 23755989
[TBL] [Abstract][Full Text] [Related]
8. [Perioperative chemotherapy vs. surgery alone in resectable gastroesophageal carcinomas. Results of the MAGIC study].
Lordick F; Siewert JR
Chirurg; 2006 Dec; 77(12):1166-7. PubMed ID: 17091285
[No Abstract] [Full Text] [Related]
9. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use?
Briasoulis E; Fatouros M; Roukos DH
Ann Surg Oncol; 2007 Oct; 14(10):2691-5. PubMed ID: 17653806
[No Abstract] [Full Text] [Related]
10. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
[TBL] [Abstract][Full Text] [Related]
11. Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial.
Ferri LE; Ades S; Alcindor T; Chasen M; Marcus V; Hickeson M; Artho G; Thirlwell MP
Ann Oncol; 2012 Jun; 23(6):1512-7. PubMed ID: 22039085
[TBL] [Abstract][Full Text] [Related]
12. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.
Ajani JA; Rodriguez W; Bodoky G; Moiseyenko V; Lichinitser M; Gorbunova V; Vynnychenko I; Garin A; Lang I; Falcon S
J Clin Oncol; 2010 Mar; 28(9):1547-53. PubMed ID: 20159816
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy for locally advanced carcinoma of the lower oesophagus and oesophago-gastric junction.
Forshaw MJ; Gossage JA; Chrystal K; Cheong K; Atkinson S; Botha A; Harper PG; Mason RC
Eur J Surg Oncol; 2006 Dec; 32(10):1114-8. PubMed ID: 16621430
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of accelerated multimodality therapy for locoregionally advanced cancer of the esophagus and gastroesophageal junction: the impact of clinical heterogeneity.
Adelstein DJ; Rice TW; Rybicki LA; Saxton JP; Videtic GM; Murthy SC; Zuccaro G; Vargo JJ; Dumot JA; Carroll MA
Am J Clin Oncol; 2007 Apr; 30(2):172-80. PubMed ID: 17414467
[TBL] [Abstract][Full Text] [Related]
15. Safety, efficacy, and long-term follow-up evaluation of perioperative epirubicin, Cisplatin, and capecitabine chemotherapy in esophageal resection for adenocarcinoma.
van der Sluis PC; Ubink I; van der Horst S; Boonstra JJ; Voest EE; Ruurda JP; Borel Rinkes IH; Wiezer MJ; Schipper ME; Siersema PD; Los M; Lolkema MP; van Hillegersberg R
Ann Surg Oncol; 2015 May; 22(5):1555-63. PubMed ID: 25564156
[TBL] [Abstract][Full Text] [Related]
16. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Cunningham D; Allum WH; Stenning SP; Thompson JN; Van de Velde CJ; Nicolson M; Scarffe JH; Lofts FJ; Falk SJ; Iveson TJ; Smith DB; Langley RE; Verma M; Weeden S; Chua YJ; MAGIC Trial Participants
N Engl J Med; 2006 Jul; 355(1):11-20. PubMed ID: 16822992
[TBL] [Abstract][Full Text] [Related]
17. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy for gastro-oesophageal cancer with epirubicin, cisplatin and fluorouracil: a single-centre experience.
Strickland AH; Karapetis CS; Yip D; Harper PG
Clin Oncol (R Coll Radiol); 2001; 13(1):66. PubMed ID: 11292143
[No Abstract] [Full Text] [Related]
19. Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma.
Kim S; Paget-Bailly S; Messager M; Nguyen T; Mathieu P; Lamfichekh N; Fein F; Fratté S; Cléau D; Lakkis Z; Jary M; Sakek N; Jacquin M; Foubert A; Bonnetain F; Mariette C; Fiteni F; Borg C
Eur J Surg Oncol; 2017 Jan; 43(1):218-225. PubMed ID: 27425578
[TBL] [Abstract][Full Text] [Related]
20. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma.
Ajani JA; Lee FC; Singh DA; Haller DG; Lenz HJ; Benson AB; Yanagihara R; Phan AT; Yao JC; Strumberg D
J Clin Oncol; 2006 Feb; 24(4):663-7. PubMed ID: 16446338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
